The 2018 Garrod lecture: Preparing for the Black Swans of resistance

Journal of Antimicrobial Chemotherapy

Volumn 73, Issue 11, 2018, Pages 2907-2915

  Livermore, David M ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL ENZYME; BETA LACTAM; BETA LACTAMASE CTX M; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIAL STRAIN; COMMUNITY; DRUG DEVELOPMENT; ENVIRONMENTAL IMPACT; ESCHERICHIA COLI; INFECTION CONTROL; MICROBIAL DIVERSITY; SWAN; BACTERIUM; DRUG EFFECT; ESCHERICHIA COLI INFECTION; GENETICS; HUMAN; LEGISLATION AND JURISPRUDENCE; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; BACTERIA; BETA-LACTAMASES; DRUG DEVELOPMENT; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS;

EID: 85055169665     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dky265     Document Type: Article

References (86)

1. Anon. Treatment Guidelines for Antimicrobial Use in Common Syndromes (India). http://icmr.nic.in/guidelines/treatment%20guidelines%20for%20antimicrobial.pdf.
2. Neuzillet Y, Naber KG, Schito G et al. French results of the ARESC study: clinical aspects and epidemiology of antimicrobial resistance in female patients with cystitis. Implications for empiric therapy. Med Mal Infect 2012; 42: 66–75.
3. Crump JA, Sjölund-Karlsson M, Gordon MA et al. Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive Salmonella infections. Clin Microbiol Rev 2015; 28: 901–37.
4. Unemo M, Bradshaw CS, Hocking JS et al. Sexually-transmitted infections: challenges ahead. Lancet Infect Dis 2017; 17: e235–79.
5. Prasad R, Singh A, Balasubramanian V et al. Extensively drug-resistant tuberculosis in India: current evidence on diagnosis and management. Indian J Med Res 2017; 145: 271–93.
6. Projan SJ, Shlaes DM. Antibacterial drug discovery: is it all downhill from here? Clin Microbiol Infect 2004; 10 Suppl 4: 18–22.
7. Payne DJ, Gwynn MN, Holmes DJ et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007; 6: 29–40.
8. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev 2011; 24: 71–109.
9. Shlaes DM, Moellering RC. The United States Food and Drug Administration and the end of antibiotics. Clin Infect Dis 2002; 34: 420–2.
10. Finch R; BSAC Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development. Regulatory opportunities to encourage technology solutions to antibacterial drug resistance. J Antimicrob Chemother 2011; 66: 1945–7.
11. Sharma P, Towse A. New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options. London, UK: Office of Health Economics, 2011. http://www.ohe.org/publications/article/new-drugs-to-tackle-antimicrobialresistance-analysis-of-eu-policy-options-21.cfm.
12. Livermore DM. Of stewardship, motherhood and apple pie. Int J AntimicrobAgents2014;43:319–22.
13. Livermore DM, Wain J. Revolutionising bacteriology to improve treatment outcomes and antibiotic stewardship. Infect Chemother 2013; 45: 1–10.
14. Minejima E, Wong-Beringer A. Implementation of rapid diagnostics with antimicrobial stewardship. Expert Rev Anti Infect Ther 2016; 14: 1065–75.
15. O’Neill J. The Review on Antimicrobial Resistance. https://amr-review.org.
16. WHO. Antimicrobial Resistance: Global Report on Surveillance. http://www.who.int/drugresistance/documents/surveillancereport/en/.
17. The Pew Charitable Trusts. Antibiotic Resistance Project. http://www.pewtrusts.org/en/projects/antibiotic-resistance-project.
18. Sciarretta K, Røttingen JA, Opalska A et al. Economic incentives for antibacterial drug development: literature review and considerations from the Transatlantic Task Force on Antimicrobial Resistance. Clin Infect Dis 2016; 63: 1470–4.
19. Outterson K, Powers JH, Daniel GW et al. Repairing the broken market for antibiotic innovation. Health Aff (Millwood) 2015; 34: 277–85.
20. Carter D, Charlett A, Conti S et al. A risk assessment of antibiotic pan-drug-resistance in the UK: Bayesian analysis of an expert elicitation study. Antibiotics (Basel) 2017; 6: E9.
21. Lowenstein R. When Genius Failed. New York: Random House, 2000.
22. Taleb NN. The Black Swan. New York: Random House, 2007.
23. 0. http://news.bbc.co.uk/1/hi/magazine/7121136.stm.
24. Woodford N, Ellington MJ. The emergence of antibiotic resistance by mutation. Clin Microbiol Infect 2007; 13: 5–18.
25. Livermore DM. Clinical significance of b-lactamase induction and stable derepression in Gram-negative rods. Eur J Clin Microbiol 1987; 6: 439–45.
26. Kaye KS, Cosgrove S, Harris A et al. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother 2001; 45: 2628–30.
27. Lynch MJ, Drusano GL, Mobley HL. Emergence of resistance to imipenem in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1987; 31: 1892–6.
28. O’Dwyer K, Spivak AT, Ingraham K et al. Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother 2015; 59: 289–98.
29. Livermore DM, Warner M, Jamrozy D et al. In vitro selection of ceftazidime/avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother 2015; 59: 5324–30.
30. Shields RK, Potoski BA, Haidar G et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime/avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 2016; 63: 1615–8.
31. MacVane SH, Pandey R, Steed LL et al. Emergence of ceftolozane/ tazobactam-resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation. Antimicrob Agents Chemother 2017;61:e01183-17.
32. Fraile-Ribot PA, Cabot G, Mulet X et al. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa. J Antimicrob Chemother 2018; 73: 658–63.
33. Tsubakishita S, Kuwahara-Arai K, Sasaki T et al. Origin and molecular evolution of the determinant of methicillin resistance in staphylococci. Antimicrob Agents Chemother 2010; 54: 4352–9.
34. Cantón R. Antibiotic resistance genes from the environment: a perspective through newly identified antibiotic resistance mechanisms in the clinical setting. Clin Microbiol Infect 2009; 15 Suppl 1: 20–5.
35. Poirel L, Kieffer N, Fernandez-Garayzabal JF et al. MCR-2-mediated plasmid-borne polymyxin resistance most likely originates from Moraxella pluranimalium. J Antimicrob Chemother 2017; 72: 2947–9.
36. Matthew M. Plasmid-mediated b-lactamases of Gram-negative bacteria: properties and distribution. J Antimicrob Chemother 1979; 5: 349–58.
37. Schmitt R. Molecular biology of transposable elements. J Antimicrob Chemother 1986; 18 Suppl C: 25–34.
38. Nicolas E, Lambin M, Dandoy D et al. The Tn3-family of replicative trans-posons. Microbiol Spectr 2015; 3: doi:10.1128/microbiolspec.MDNA3-0060-2014.
39. Livermore DM. Fourteen years in resistance. Int J Antimicrob Agents 2012;39:283–94.
40. Livermore DM, Hope R, Reynolds R et al. Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: links to prescribing change? J Antimicrob Chemother 2013; 68: 2667–74.
41. Liu PY, Gur D, Hall LM et al. Survey of the prevalence of b-lactamases amongst 1000 Gram-negative bacilli isolated consecutively at the Royal London Hospital. J Antimicrob Chemother 1992; 30: 429–47.
42. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165–74.
43. Nicolas-Chanoine MH, Bertrand X, Madec JY. Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev 2014; 27: 543–74.
44. Ciesielczuk H, Doumith M, Hope R et al. Characterization of the extraintestinal pathogenic Escherichia coli ST131 clone among isolates recovered from urinary and bloodstream infections in the United Kingdom. J Med Microbiol 2015; 64: 1496–503.
45. Clark C. The Sleepwalkers: How Europe Went to War in 1914. London: AllenLane,2013.
46. D’Costa VM, McGrann KM, Hughes DW et al. Sampling the antibiotic resis-tome. Science 2006; 311: 374–7.
47. D’Costa VM, Mukhtar TA, Patel T et al. Inactivation of the lipopeptide antibiotic daptomycin by hydrolytic mechanisms. Antimicrob Agents Chemother 2012; 56: 757–64.
48. Shaw KJ, Rather PN, Hare RS et al. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 1993; 57: 138–63.
49. Doi Y, Wachino JI, Arakawa Y. Aminoglycoside resistance: the emergence of acquired 16S ribosomal RNA methyltransferases. Infect Dis Clin North Am 2016; 30: 523–37.
50. Patel R, Piper K, Cockerill FR et al. The biopesticide Paenibacillus popilliae has a vancomycin resistance gene cluster homologous to the enterococcal VanA vancomycin resistance gene cluster. Antimicrob Agents Chemother 2000; 44: 705–9.
51. Guardabassi L, Perichon B, van Heijenoort J et al. Glycopeptide resistance vanA operons in Paenibacillus strains isolated from soil. Antimicrob Agents Chemother 2005; 49: 4227–33.
52. Berger-Bächi B. Genetic basis of methicillin resistance in Staphylococcus aureus. Cell Mol Life Sci 1999; 56: 764–70.
53. Curtis NA, Orr D, Ross GW et al. Affinities of penicillins and cephalosporins for the penicillin-binding proteins of Escherichia coli K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979; 16: 533–9.
54. Hashizume T, Ishino F, Nakagawa J et al. Studies on the mechanism of action of imipenem (N-formimidoylthienamycin) in vitro: binding to the penicillin-binding proteins (PBPs) in Escherichia coli and Pseudomonas aeruginosa, and inhibition of enzyme activities due to the PBPs in E. coli. J Antibiot 1984; 37: 394–400.
55. Beesley L. The Loss of the SS Titanic: Its Story and Lessons. Boston and New York: Houghton Mifflin, 1912.
56. Philippon A, Labia R, Jacoby G. Extended-spectrum b-lactamases. Antimicrob Agents Chemother 1989; 33: 1131–6.
57. Watanabe M, Iyobe S, Inoue M et al. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991; 35: 147–51.
58. Johnson AP, Woodford N. Global spread of antibiotic resistance: the example of New Delhi metallo-b-lactamase (NDM)-mediated carbapenem resistance. J Med Microbiol 2013; 62: 499–513.
59. Livermore DM, Mushtaq S, Warner M et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011; 55: 390–4.
60. Livermore DM, Mushtaq S, Warner M et al. In vitro activity of cefepime/ zidebactam (WCK 5222) against Gram-negative bacteria. J Antimicrob Chemother 2017; 72: 1373–85.
61. Livermore DM, Warner M, Mushtaq Setal. Interactionsof OP0595, anovel triple-action diazabicyclooctane, with b-lactams against OP0595-resistant Enterobacteriaceae mutants. Antimicrob Agents Chemother 2015; 60: 554–60.
62. 0. J Antimicrob Chemother 2015; 70: 2779–86.
63. Mushtaq S, Vickers A, Woodford N et al. Nacubactam (RG6080) alone and in combination against metallo-b-lactamase (MBL)-producing Enterobacteriaceae. In: Posters of the Twenty-eighth European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain, 2018. Poster P1033. ESCMID, Basel, Switzerland.
64. WHO. Antibacterial Agents in Clinical Development. http://www.who.int/medicines/news/2017/IAU_AntibacterialAgentsClinicalDevelopment_webfi nal_2017_09_19.pdf.
65. Mushtaq S, Vickers A, Woodford N et al. Potentiation of cefepime by the boronate VNRX-5133 versus Gram-negative bacteria with known b-lactamases. In: Posters of the Twenty-eighth European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain, 2018. Poster P1536. ESCMID, Basel, Switzerland.
66. Kohira N, West J, Ito A et al. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother 2015; 60: 729–34.
67. Reck F, Bermingham A, Blais J et al. Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae – identification of LYS228. Bioorg Med Chem Lett 2018; 28: 748–55.
68. Shlaes DM. The clinical development of antibacterial drugs: a guide for the discovery scientist. In: Topics in Medicinal Chemistry. Fisher JF, Mobashery S, Miller MJ, eds. Berlin, Heidelberg: Springer, 2018; 149–63.
69. Qin X, Tran BG, Kim MJ et al. A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronida-zole versus meropenem for complicated intra-abdominal infections in hospi-talised adults in Asia. Int J Antimicrob Agents 2017; 49: 579–88.
70. Stone GG, Bradford PA, Yates K et al. In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial pro-gramme for the treatment of complicated urinary tract infections. J Antimicrob Chemother 2017; 72: 1396–9.
71. Carmeli Y, Armstrong J, Laud PJ et al. Ceftazidime/avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 2016; 16: 661–73.
72. Livermore DM, Hope R, Mushtaq S et al. Orthodox and unorthodox clavulanate combinations against extended-spectrum b-lactamase producers. Clin Microbiol Infect 2008; 14 Suppl 1: 189–93.
73. Sader HS, Castanheira M, Mendes RE et al. Antimicrobial activity of high-proportion cefepime/tazobactam (WCK 4282) against a large number of Gram-negative isolates collected worldwide in 2014. Antimicrob Agents Chemother 2017; 61: e02409-16.
74. Livermore DM, Mushtaq S, Warner M et al. Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens. J Antimicrob Chemother 2018; 73: 126–33.
75. Yahav D, Paul M, Fraser A et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 2007; 7: 338–48.
76. Kim PW, Wu YT, Cooper C et al. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 2010; 51: 381–9.
77. Barnes MD, Winkler ML, Taracila MA et al. Klebsiella pneumoniae carbapenemase-2 (KPC-2), substitutions at Ambler position Asp179, and resistance to ceftazidime/avibactam: unique antibiotic-resistant phenotypes emerge from b-lactamase protein engineering. MBio 2017; 8: e00528-17.
78. Livermore DM, Meunier D, Hopkins KL et al. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015–16. J Antimicrob Chemother 2017; 73: 648–57.
79. Mojica MF, Ouellette CP, Leber A et al. Successful treatment of bloodstream infection due to metallo-b-lactamase-producing Stenotrophomonas maltophilia in a renal transplant patient. Antimicrob Agents Chemother 2016; 60: 5130–4.
80. Davido B, Fellous L, Lawrence C et al. Ceftazidime/avibactam and aztreonam, an interesting strategy to overcome b-lactam resistance conferred by metallo-b-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2017; 61: e01008-17.
81. Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob Agents Chemother 1998; 42: 1303–4.
82. Michalopoulos AS, Tsiodras S, Rellos K et al. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11: 115–21.
83. Jordens JZ, Slack MP. Haemophilus influenzae: then and now. Eur J Clin Microbiol Infect Dis 1995; 14: 935–48.
84. Clift C, Salisbury DM. Enhancing the role of vaccines in combatting antimicrobial resistance. Vaccine 2017; 35: 6591–3.
85. Huttner A, Hatz C, van den Dobbelsteen G et al. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis 2017; 17: 528–37.
86. Czaplewski L, Bax R, Clokie M et al. Alternatives to antibiotics—a pipeline portfolio review. Lancet Infect Dis 2016; 16: 239–51.